



Contra Costa Health Plan
P&T Formulary Update
March 23, 2020

Volume 13

Changes effective: 5/1/2020

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On March 19, 2020 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
- Inhaled Anticholinergics - Idiopathic Pulmonary Fibrosis - Glucagon - PCSK9 Inhibitors - Coronary Vasodilators - Direct Acting Anticoagulants	- First Generation Antihistamines - GI Antispasmodics - Pulmonary Biologics - Cystic Fibrosis Medications - GLP-1 Agents
Drug Monographs	
Rybelsus (semaglutide)	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> - Parsabiv (etelcalcetide) - Nicotinamide - Compounded Medications - Esbriet (pirfenidone) - Ofev (nintedanib) <u>Updates were made to the criteria for the following agents:</u> - Dupixent (dupilumab) - Rozerem (ramelteon) <u>Criteria reviewed and unchanged:</u> - First Generation Antihistamines - GI Antispasmodics - Pulmonary Biologics - Cystic Fibrosis - GLP-1 Agents	

The following drugs were added to the CCHP formulary:

- Lyrica (pregabalin)
- Xarelto 2.5 mg (rivaroxaban)
- Onfi (clobazam)
- Novolog (insulin aspart)
- Pulmicort Respules (budesonide)
- Pulmicort Flexhaler (budesonide)
- Incruse Ellipta (umeclidinium)
- Stiolto Respimat (tiotropium/olodaterol)
- Basqsimi (glucagon intranasal)

Guest Speaker(s)

- None

CCHP P&T Committee approved the following modifications to the formulary:

Medication Name & Dosage Strength	Approved Formulary Changes
Lyrica (pregabalin)	Added to formulary, Tier 1
Xarelto 2.5 mg (rivaroxaban)	Added to formulary, Tier 2 QL
Onfi (clobazam)	Added to formulary, Tier 2 QL
Novolog (insulin aspart)	Added to formulary, Tier 1
Pulmicort Respules (budesonide)	Added to formulary, Tier 2 QL
Pulmicort Flexhaler (budesonide)	Added to formulary, Tier 1
Incruse Ellipta (umeclidinium)	Added to formulary, Tier 2 QL
Stiolto Respimat (tiotropium/olodaterol)	Added to formulary, Tier 1
Baqsimi (glucagon intranasal)	Added to formulary, Tier 1
Eliquis (apixaban) Dose Pack	Added to formulary, Tier 2 QL

New Product Reviews (including new indications)

- | | |
|--|--|
| <ul style="list-style-type: none"> • DiMentho (diclofenac/menthol) • Gloperba (colchicine) • Kanjinti (trastuzumab-anns) • Vumerity (diroximel fumerate) • Biorphen (phenylephrine) • Ogivri (trastuzumab-dkst) • Olumiant (baricitinib) • Caldolor (ibuprofen) • Truxima (rituximab-abbs) • Ziextenzo (pegfilgrastim-bmez) • Reblozyl (luspatercept-aamt) • Pretomanid (pretomanid) • Nplate (romiplostim) • Adakveo (crizanlizumab) • Amzeeq (minocycline) • Brukinsa (zanubrutinib) • Asceniv (immunoglobulin G-slra) • Aborica LD (isotretinoin) | <ul style="list-style-type: none"> • Givlaari (givosiran) • Gabacaine (gabapentin/lidocaine) • Carbocaine w/Ne0-Cobefrin (mepivacaine/levonordef) • Oxbryta (voxelotor) • Eyelea (afilbercept) • Prilo Patch Kit (lido/prilo cream/lido patch) • Egrifta (tesamorelin) • Consensi (amlodipine/celecoxib) • Jatenzo (testosterone undecanoate) • Secuado (asenapine) • Microvix LP (lido/prilo/benzalkon) • Vyondys 53 (golodirsen) • Talicia (omeprazole/amox/rifabutin) • Padcev (enfortumab) • Enhertu (fam-trastuzumab-deruxtecn-nxki) |
|--|--|

- | | |
|---|---|
| <ul style="list-style-type: none">• Recarbrio (imipenem/cilastatin/relebactam)• Ubrelvy (ubrogepant)• Valtoco (diazepam nasal)• Esperoct (antihemophilic factor glycoperylated-exei)• Avvakit (avapritinib) | <ul style="list-style-type: none">• Zirabev (bevacizumab-bvzr)• Divigel (estradiol)• Quzyttir (cetirizine)• Xeljanz XR (tofacitinib XR)• Caplyta (lumateperone)• Tepezza (teprotumumab-trbw) |
|---|---|